Description: Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
Home Page: www.rakovinatherapeutics.com
999 West Broadway
Vancouver,
BC
V5Z 1K5
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey A. Bacha B.Sc., M.B.A. | Executive Chairman |
| Dr. Mads Daugaard Ph.D. | President, CEO & Chief Scientific Officer |
| Mr. David Hyman CA, CBV | CFO & Corporate Secretary |
| Dr. John Langlands Ph.D. | Chief Operating Officer |
| Ms. Michelle Seltenrich M.B.A., MBA | Director of Corporate Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |